Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
nilotinib (tasigna) (1 trial)
Leukemia (Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)
Leukemia, Myeloid (Phase 2)
Trials (1 total)
Trial APIs (1 total)